Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer Clinical Trial

Official title:

A Non-randomized, Prospective Clinical Study of Pegylated Liposomal Doxorubicin and PD-1 in the Second-line Treatment of Relapse or Metastatic Muscle Invasive Bladder Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04101812
• Other study ID #: DMSMIBC-01
• Status: Recruiting
• Phase: Phase 2
• Start date: September 17, 2019
• Est. completion date: May 31, 2021

Study information

• Verified date: September 2019
• Source: Tianjin Medical University Second Hospital
• Contact: Haitao Wang
• Phone: (022)28331788
• Email: peterrock2000[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Despite primary surgical management of muscle invasive bladder cancer (MIBC) with radical cystectomy and pelvic lymphnode dissection, up to 50% of patients will eventually develop tumours at distant sites, owing to pre-existing disseminated occult micrometastases. The first line treatment for relapse or metastatic MIBC is gemcitabine and cisplatin. After the failure of first line treatment, second line chemotherapy drugs can be chosen from doxorubicin, docetaxel, pemetrexed, etc. This non-randomized, prospective study aims to explore the efficacy and safety of PEGylated liposomal doxorubicin and PD-1 in second line treatment of MIBC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: May 31, 2021
• Est. primary completion date: May 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Clinically confirmed muscle-invasive bladder cancer.

• Histologically confirmed by HE staining or IHC staining.

• Life expectancy of greater than or equal to 3 months.

• KPS performance >60, ECOG performance status =2.

• Adequate liver function with a bilirubin up to 1.5 x ULN. Transaminases up to 2.5 x ULN; for liver metastasis, transaminases up to 5 x ULN.

• Adequate bone marrow function, as defined by neutrophils count of =1.5×109/L, platelet count=80×109/L, hemoglobin=9.0g/dL.

• Adequate renal function (serum creatinine =1.25 times the ULN, and the release rate of which = 60ml/min).

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

• Negative serum pregnancy test for female subjects with reproductive potential =< 7 days prior to registration, for women of childbearing potential only. All female patients of childbearing age and all male patients with partners of childbearing age should use a reliable method of contraception, such as the barrier method, throughout the study and for 8 weeks after last treatment.

• Sign the informed consent before any trial related activities.

Exclusion Criteria:

• A prior malignancy, other than non-melanoma skin cancer, carcinoma in situ, localized prostate cancer or ductal carcinoma in situ treated by surgery unless they have completed therapy at least 5 years prior to start of study and have no evidence of recurrent or residual disease

• Chemotherapy, biological therapy or other anti-cancer drugs = 28 days prior to pre-registration

• Factors that would affect taking medicine orally, such as dysphagia, chronic diarrhea and intestinal obstruction

• History of arterial/venous thrombus = 6 months prior to registration, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism

• History or tendency of gastrointestinal hemorrhage caused by severe gastroesophageal varices or other reasons.

• Dysfunction of blood coagulation: prothrombin time (PT)>16s, activated partial thromboplastin time (APTT) >43s, thrombin time (TT) >21s, INR >2, fibrinogen < 2g/L, bleeding tendency or under thrombolytic or anticoagulant therapy

• Uncontrolled intercurrent illness including, but not limited to:

ongoing or active infection; poor controlled diabetes (FBG > 10 mmol/L); urine protein =++, and UAE > 1.0g/24h; myocardial ischemia; congestive heart failure; cardiac arrhythmia or cardiac insufficiency; LVEF < 50%

• Unhealed wounds, ulcers or fractures

• Abuse of psychotropic substances or mentally disturbed

• History of HIV, organ transplantation or any other acquired, congenital immunodeficiency diseases

• Patients evaluated not suitable for the study in the opinion of investigators

Related Conditions & MeSH terms

• Muscle Invasive Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• pegylated liposomal doxorubicin (PLD)
PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
• PD-1
PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.

Locations

Country	Name	City	State
China	Tianjin Medical Unversity Second Hospital	Tianjin	Tianjin

Sponsors (2)

Lead Sponsor	Collaborator
Tianjin Medical University Second Hospital	CSPC Pharmaceutical Group Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease control rate	Disease control rate defined as confirmed complete response or partial response or stable disease under RECIST 1.0 criteria.	at least 10 months
Primary	Objective response rate	Objective response rate defined as confirmed complete response or partial response under RECIST 1.0 criteria.	at least 10 months
Secondary	Progression free survival	Progression-free survival estimated using Kaplan-Meier methods is defined as the time from registration to the earlier of death or disease progression.	at least 10 months
Secondary	Overall survival	Overall survival estimated using Kaplan-Meier methods is defined as the time from treatment initiation to death by any cause	at least 10 months